

**DCAT**  
**TOP** ↑  
**Industry**  
**NEWS**

***BUSY WEEK?** Here are the  
TOP INDUSTRY NEWS stories  
you might have missed, as  
selected by DCAT Editorial  
Director Patricia Van Arnum.*

**1. [BMS to Acquire IFM Therapeutics in a Deal Worth Up to \\$2.3 Billion](#)**

Bristol-Myers Squibb (BMS) has agreed to acquire IFM Therapeutics, a company developing drugs for cancer, autoimmunity, and inflammatory disorders, in a deal worth up to \$2.3 billion. [Read More](#)

**2. [Merck & Co. to Buy Mfg Facility for Animal Health from Shire](#)**

Merck & Co. plans to purchase from Shire a manufacturing facility in Krems an der Donau, Austria for its animal health business with the intention to expand its global vaccine manufacturing. [Read More](#)

**3. [FDA Advisory Committee Votes Down J&J's Arthritis Drug](#)**

A FDA advisory committee did not recommend for approval Plivensia (sirukumab), a drug by Johnson & Johnson's (J&J) Janssen Biotech, for treating moderately to severely active rheumatoid arthritis. The company said it will continue discussions with the FDA. This news is part of *DCAT Value Chain Insights Pipeline News*. [Read More](#)

**4. [Endo Records Second-Quarter Loss of Nearly \\$1.4 Billion](#)**

Endo International, a specialty pharmaceutical and generic-drug company, reported a second-quarter loss of \$1.4 billion, which included impairment charges of \$725 million relating to its US generic and branded pharmaceutical business. The company also increased its product liability reserves by \$775 million to settle claims on its vaginal mesh products. [Read More](#)

**5. [CDMO Avara Pharmaceuticals Buys Sterile Mfg Plant from Pfizer](#)**

Avara Pharmaceutical Services, a Norwalk, Connecticut-headquartered CDMO, has agreed to acquire Pfizer's sterile manufacturing facility in Liscate, Italy. [Read More](#)

**6. [Mallinckrodt To Acquire InfaCare in a \\$425-Million Deal](#)**

Mallinckrodt, a specialty pharmaceutical company, has agreed to acquire InfaCare Pharmaceutical, a Treviso, Pennsylvania-based specialty pharmaceutical company focused on neonatal and pediatric drugs, in a deal worth up to \$425 million. [Read More](#)

**7. [Cambrex Invests \\$24 Million in High-Potency API Manufacturing](#)**

Cambrex, a CMO of small-molecule active pharmaceutical ingredients (APIs), has invested \$24 million in a new facility to manufacture highly potent APIs at its site in Charles City, Iowa. [Read More](#)

**8. [Lonza Acquires Micronization Firm Micro-Macinazione](#)**

Lonza has acquired Micro-Macinazione, a Monteggio, Switzerland-based provider of micronization services, from Cross Equity, a Swiss investment firm. [Read More](#)

**9. [Valeant Receives Complete Response Letter for Manufacturing](#)**

Valeant Pharmaceuticals has received a second Complete Response Letter from the FDA regarding its new drug application for its eye-care product, latanoprostene bunod ophthalmic solution. [Read More](#)

**10. [Senate Passes User-Fees Bill; FDA Updates Proposed OTC User-Fee](#)**

## Program

The US Senate voted to pass *The FDA Reauthorization Act*, which reauthorizes user fees for prescription drugs, generic drugs, and biosimilars. In a separate move, the FDA released draft goals and procedures for a potential user-fee program for nonprescription or over-the-counter (OTC) drugs. [Read More](#)

***The DCAT organization is happy to provide this service to its members each Friday.  
Have a great weekend!***

## **About Top Industry News**

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



**The Drug, Chemical & Associated Technologies Association (DCAT)** is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691  
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599  
[www.dcat.org](http://www.dcat.org)

Drug, Chemical, & Associated Technologies Association, One Union Street,  
Suite 208, Robbinsville, NJ 08691

SafeUnsubscribe™ {recipient's email}

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by [dcatnews@dcat.org](mailto:dcatnews@dcat.org)